Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer
 patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This
 testing broadens treatment options for patients, however there are other gene mutations with
 corresponding targeted treatments that are not routinely tested for. This study will evaluate
 the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine
 Comprehensive Assay v3, to profile stage IV lung cancer patients.
Inclusion Criteria:

 -  Age ≥ 18 years of age

 -  Pathologic or cytologic confirmation of lung adenocarcinoma (mixed adenocarcinoma and
 sarcomatoid features permitted)

 -  Stage IV disease

 -  Sufficient FFPE tumour tissue for OCCP testing

 -  Performance status 0-2

 -  Candidates for targeted therapy (TKIs) and/or clinical trials as determined by the
 patient's medical oncologist

 -  Prognosis > 6 months

 -  Known translocations of RET, MET exon14 skipping variants, or MET amplification are
 allowed

 Exclusion Criteria:

 ● Patients with known EGFR, KRAS, BRAF and ERBB2 mutations or ALK or ROS1 fusions at study
 entry unless acquired resistance to molecularly targeted therapy